EP0160980B1 - Procédé pour déterminer l'activité cholinestérasique - Google Patents
Procédé pour déterminer l'activité cholinestérasique Download PDFInfo
- Publication number
- EP0160980B1 EP0160980B1 EP85105635A EP85105635A EP0160980B1 EP 0160980 B1 EP0160980 B1 EP 0160980B1 EP 85105635 A EP85105635 A EP 85105635A EP 85105635 A EP85105635 A EP 85105635A EP 0160980 B1 EP0160980 B1 EP 0160980B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substrate
- determination
- che
- activity
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
- C12Q1/46—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase involving cholinesterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
Definitions
- This invention relates to a method for determining cholinesterase activity, characterized by using, as a substrate, a protocatechuoylcholine halide derivative represented by the general formula (I):
- X is a halogen atom
- ChE cholinesterase
- PCI protocatechuoylcholine iodide
- An object of the present invention is to provide a novel method for determining cholinesterase activity.
- Another object of the present invention is to provide choline derivative which can be used as the substrate in the method.
- UV spectra of PCI and protocatechnic acid are shown in Fig. 2.
- PCI gives choline and protocachuic acid.
- Choline has no UV absorption at a wave length longer than 300 nm.
- Protocatechuic acid has almost no UV absorption at a wave length longer than 340 nm. Therefore, when PCI is used as a substrate for determining ChE activity and the reaction is followed at a determination wave length of 340 to 360 nm, a decrease in amount of the substrate PCI can accurately be followed.
- the determination wave length is 240 nm and hence serious interference by blood components occurs in initial absorptions.
- the substrate PCI is very stable to nonenzymatic hydrolysis. For example, hydrolysis hardly occured under the conditions of 37 C in a 50 mM barbital buffer solution having a pH of 8.5 for 90 minutes (see Fig. 6). This result indicates that nonenzymatic hydrolysis is negligible in the determination.
- a buffer for keeping the pH constant there can be used barbiturates, phosphates, pyrophosphates, glycine, glycylglycine, tris(hydroxymethyl)aminomethane, etc. Any buffer other than those described above can be used so long as it can retain its buffer capacity in the pH range from 7.5 to 10.0.
- the Km value of PCI for ChE is substantially the same as that of benzoylcholine and is 2.6 x 10- 5 mol/liter in a 50 mM tris-maleic acid buffer solution (pH 8.2) and 5.88 x 10- 5 mol/liter in a 50 mM barbital buffer solution (pH 8.5). Since the Kn value of PCI is sufficiently small, the reaction can be carried out at sufficient substrate concentration in the reaction system of the determination method of this invention, and the range of linearity with the lapse of time is enlarged, so that the determination can sufficiently be carried out for a high unit of the activity.
- the optimum pH of ChE was 8.5 to 8.6 in a 50 mM barbital buffer solution (see Fig. 5).
- PCI is stable to noenzymatic hydrolysis at pH 8.5, and hence the determination method of this invention makes it possible to carry out the reaction at the optimum pH of ChE.
- Coexisting substances for example, up to 20 mg/dl of ascorbic acid, up to 20 mg/dl of uric acid, up to 500 mg/dl of glucose, up to 200 mg/dl of hemoglobin, up to 5 g/dl of albumin, up to 20 mg/dl of bilirubin, and up to 50 mg/dl of glutathione (reduced form) caused no trouble in addition tests (see Figs. 7 to 13).
- EDTA'2Na ethylenediamine tetraacetic acid disodium salt
- citrate citrate
- heparin citrate
- oxalate citrate
- dihydrogenoxalic acid dihydrogenoxalic acid
- the determination method of this invention is very hardly affected by the coexisting substances and is an excellent method for determining cholinesterase activity in which the causes of error of determined value in the heretofore well-known determination methods are greatly removed.
- cholinesterases there are known two kinds, namely, pseudo-cholinesterase existing in serum and true-cholinesterase existing in erythrocyte.
- One whose activity is usually determined in a clinical examination is pseudo-cholinesterase in serum, but since serum is contamitated with true-cholinesterase in some cases, a substrate which reacts selectively pseudo-cholinesterase alone is preferable for the object of the examination.
- PCI used in the method of this invention is a substrate having a very high specity which reacts well with pseudo-cholinesterase but hardly reacts with true-cholinesterase.
- an examination for abnormal pseudo-cholinesterase is important from the viewpoint of the relationship between anesthetics and pseudo-cholinesterase.
- the determination method of this invention is simple and plain with regard to the reaction mechanism and hence is very suitable as a method of examination for abnormal pseudo-cholinsterase.
- the method for determining ChE activity of this invention is, as described above, free from the problems of the conventional methods is various points.
- the advantages of this invention are as described below.
- the method for determining ChE activity of this invention is free from the defects of the conventional methods, has many advantages and characteristics, permits accurate and simple determination of ChE activity, and can sufficiently contribute to determination of ChE activity in daily clinical examinations.
- the reaction mixture was adjusted to pH 2 with cold 5 N HCI and extracted with 200 ml of ethyl acetate and then 100 ml thereof, and the ethyl acetate layers were combined, thereafter washed with an aqueous sodium chloride solution, and then dried over anhydrous magnesium sulfate. Then, the solvent was distilled off under reduced pressure to obtain 25 g of an oily substance. The substance was recrystallized from ethyl acetate/n-hexane to obtain 9.2 g of 0,0'-dicarbobenzoxyprotocatechuic acid.
- Fig. 3 shows the results of measuring twice each of time courses for serum and diluted serum.
- the pH of the barbital buffer solution was adjusted at 25 C.
- CONSERA I manufactured by Nissui Pharmaceutical Co., Ltd.
- the serum was diluted with a 0.877% aqueous sodium chloride solution.
- Example 1 The pH of the buffer solution of (1) in Example 1 was varied from 7.4 to 9.2 and the optimum pH for ChE in said method was determined. This determination was carried out entirely according to Example 1 except for the pH of the buffer. The result obtained is shown in Fig. 5. Under these conditions, the optimum pH was 8.5 to 8.6.
- Example 2 To 2.0 ml of the buffer of (1) in Example 1 was added 0.1 ml of the substrate solution of (3), and the resulting solution was placed in a heat insulating cuvette having a temperature of 37° C. The change of optical absorbance at a wave length of 340 nm was followed with the lapse of time, whereby the stability of the substrate to nonenzymatic hydrolysis was examined. As a result, the substrate was almost stable up to 90 minutes as shown in Fig. 6. Since the substrate PCI is stable at the optimum pH of 8.5, it is unnecessary to measure a reagent blank value for each sample.
- Example 1 The influence of the following additives in the reaction system was examined according to the determination method in Example 1. The determination results are shown in terms of relative activity (%) in Figs. 7 to 14. As to hemoglobin, the relative activity was 97.3% in the case of its addition in an amount of 300 mg/dl, and hence the determination is possible up to about this amount. Since NaF is an inhibitor of pseudocholinesterase, determination of ChE activity by any method generally gives no accurate determined value in the presence of NaF. Therefore, from the result for NaF in Fig. 14, NaF cannot be used as an anti-coagulant in determining pseudo-cholinesterase activity.
- the ChE activity value is calculated from the following equation.
- the serum dilution and the enzyme activity are proportional to each other in the manner of a straight chain passing through the origin very sufficiently.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59093547A JPS60238000A (ja) | 1984-05-10 | 1984-05-10 | 新規なコリンエステラ−ゼ活性測定法 |
JP93547/84 | 1984-05-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0160980A2 EP0160980A2 (fr) | 1985-11-13 |
EP0160980A3 EP0160980A3 (en) | 1987-10-07 |
EP0160980B1 true EP0160980B1 (fr) | 1991-10-16 |
Family
ID=14085284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP85105635A Expired - Lifetime EP0160980B1 (fr) | 1984-05-10 | 1985-05-08 | Procédé pour déterminer l'activité cholinestérasique |
Country Status (4)
Country | Link |
---|---|
US (1) | US4717659A (fr) |
EP (1) | EP0160980B1 (fr) |
JP (1) | JPS60238000A (fr) |
DE (1) | DE3584385D1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0650997B2 (ja) * | 1986-04-15 | 1994-07-06 | 日東紡績株式会社 | コリンエステラ−ゼ活性の新規測定方法 |
CA2095495C (fr) * | 1992-06-01 | 2002-06-04 | Stephen Carl Hasselberg | Dosage de la cholinesterase serique |
DK1133571T3 (da) | 1998-11-23 | 2006-10-23 | Proteome Sciences Inc | Fremgangsmåder og sammensætning til smertebehandling |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2914721A1 (de) * | 1978-04-17 | 1979-10-18 | Kyowa Hakko Kogyo Kk | Verfahren zur bestimmung der cholinesterase-aktivitaet sowie fuer dieses verfahren verwendbare cholin-derivate |
JPS5854800B2 (ja) * | 1978-04-17 | 1983-12-06 | 協和醗酵工業株式会社 | コリン誘導体を用いるコリンエステラ−ゼ活性測定法 |
JPS5721352A (en) * | 1980-07-11 | 1982-02-04 | Shinotesuto Kenkyusho:Kk | Novel substance for measuring cholineesterase activity and method thereof |
JPS5935599B2 (ja) * | 1980-12-25 | 1984-08-29 | 株式会社 シノテスト研究所 | コリンエステラ−ゼ活性測定法 |
JPS603838B2 (ja) * | 1981-04-08 | 1985-01-30 | 富士レビオ株式会社 | コリンエステラ−ゼの活性測定法 |
JPS57144999A (en) * | 1981-03-04 | 1982-09-07 | Fujirebio Inc | Measurement of activity of cholinesterase |
EP0060059B1 (fr) * | 1981-03-04 | 1985-08-21 | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. | Méthode de détermination de l'activité de la cholinestérase et solution diagnostique pour cette méthode |
JPS603839B2 (ja) * | 1981-04-08 | 1985-01-30 | 富士レビオ株式会社 | コリンエステラ−ゼの活性測定法 |
JPS60197643A (ja) * | 1984-03-21 | 1985-10-07 | Nitto Boseki Co Ltd | 新規コリン誘導体 |
-
1984
- 1984-05-10 JP JP59093547A patent/JPS60238000A/ja active Granted
-
1985
- 1985-05-06 US US06/731,069 patent/US4717659A/en not_active Expired - Lifetime
- 1985-05-08 EP EP85105635A patent/EP0160980B1/fr not_active Expired - Lifetime
- 1985-05-08 DE DE8585105635T patent/DE3584385D1/de not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
ENZYME NOMENCLATURE, 1978, IUB, Academic Press, New York, 1979, pp. 234-235 * |
Also Published As
Publication number | Publication date |
---|---|
JPH0542278B2 (fr) | 1993-06-28 |
JPS60238000A (ja) | 1985-11-26 |
US4717659A (en) | 1988-01-05 |
EP0160980A2 (fr) | 1985-11-13 |
EP0160980A3 (en) | 1987-10-07 |
DE3584385D1 (de) | 1991-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bender et al. | The determination of the concentration of hydrolytic enzyme solutions: α-chymotrypsin, trypsin, papain, elastase, subtilisin, and acetylcholinesterase1 | |
US4251629A (en) | Determination of hydrogen peroxide | |
EP0007787B1 (fr) | Procédé et réactif pour la détermination quantitative de peroxyde d'hydrogène | |
EP0159870B1 (fr) | Méthode de détermination des composés mercapto et réactif pour sa mise en oeuvre | |
US4637979A (en) | Composition and test device for determining the presence of leukocytes containing a zwitterion coupling agent | |
EP0295034B1 (fr) | Composés hydrolysables libérant des agents de transfert d'electrons et leur utilisation analytique | |
EP0157326A2 (fr) | Composition et dispositif d'essai pour déterminer la présence de leucocytes, de l'estérase et de la protéase dans un échantillon d'essai | |
US4824779A (en) | Method for the determination of the reduced form of nicotinamide adenine dinucleotide | |
EP0396584B1 (fr) | Determimation quantitative de salicylates ou nucleotides de pyridine reduits | |
EP0488756B1 (fr) | Reactif oxydable produisant d'un couleur | |
EP0160980B1 (fr) | Procédé pour déterminer l'activité cholinestérasique | |
EP0241915B1 (fr) | Procédé pour déterminer l'activité de cholinestérase | |
EP0037742B1 (fr) | Procédé et réactif de détermination des hydroxystéroides | |
US4983756A (en) | Novel choline derivative and method for detemining serum cholinesterase activity using the same | |
EP0155825A2 (fr) | Dérivés de choline | |
JPH0571239B2 (fr) | ||
US5081274A (en) | 4-acyl-2,6-dihalophenyl-phosphoric acid derivatives useful in the determination of acid phosphatase activity | |
US5350678A (en) | Method of differential assay for α-amylase isozymes and a kit for the same | |
US4983512A (en) | Reagent for determination of acid phosphatase | |
US5227291A (en) | Method for determination of acid phosphatase activity using 4-acyl-2, 6-dihalophenyl phosphoric acid derivatives | |
JPS6121546B2 (fr) | ||
JP3740716B2 (ja) | アシルチオコリン誘導体およびその用途 | |
JPH03119997A (ja) | 成分の測定法 | |
Lorentz | Continuous monitoring of prostatic acid phosphatase using self-indicating substrates | |
JPS5854800B2 (ja) | コリン誘導体を用いるコリンエステラ−ゼ活性測定法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): CH DE FR LI |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): CH DE FR LI |
|
17P | Request for examination filed |
Effective date: 19871201 |
|
17Q | First examination report despatched |
Effective date: 19890824 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NITTO BOSEKI CO., LTD. |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): CH DE FR LI |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19911016 |
|
REF | Corresponds to: |
Ref document number: 3584385 Country of ref document: DE Date of ref document: 19911121 |
|
EN | Fr: translation not filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20040413 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20040422 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |